(Q37290939)

19 August 2017

1 reference

title

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection (English)

1 reference

19 August 2017

1 reference

Ariela Benigni

2

0 references

Giuseppe Remuzzi

object named as

Giuseppe Remuzzi

series ordinal

3

0 references

Norberto Perico

series ordinal

1

object named as

Norberto Perico

1 reference

19 August 2017

publication date

10 October 2008

1 reference

Nature Reviews Drug Discovery

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

936-953

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2685

19 August 2017

exact match

0 references

cites work

Strategies for making more organs available for transplantation

1 reference

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

31 March 2020

1 reference

Progression of renal disease and renal hypertrophy

31 March 2020

1 reference

Gene expression profiling of vascular endothelial cells exposed to fluid mechanical forces: relevance for focal susceptibility to atherosclerosis

31 March 2020

1 reference

Activation of mesangial cell signaling cascades in response to mechanical strain

31 March 2020

1 reference

Podocyte injury and targeting therapy: an update

31 March 2020

1 reference

Human podocytes possess a stretch-sensitive, Ca2+-activated K+ channel: potential implications for the control of glomerular filtration

31 March 2020

1 reference

Activation of a local tissue angiotensin system in podocytes by mechanical strain

31 March 2020

1 reference

Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass

31 March 2020

1 reference

Cellular responses to protein overload: key event in renal disease progression

31 March 2020

1 reference

Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole

31 March 2020

1 reference

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

31 March 2020

1 reference

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

31 March 2020

1 reference

Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention

31 March 2020

1 reference

Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies.

31 March 2020

1 reference

Paracrine stimulation of human renal fibroblasts by proximal tubule cells

31 March 2020

1 reference

Overview of factors contributing to the pathophysiology of progressive renal disease

31 March 2020

1 reference

Role of cellular infiltrates in response to proteinuria.

31 March 2020

1 reference

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

31 March 2020

1 reference

Proteinuria and the risk of developing end-stage renal disease

31 March 2020

1 reference

Pathophysiology of Progressive Nephropathies

31 March 2020

1 reference

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

31 March 2020

1 reference

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

31 March 2020

1 reference

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

31 March 2020

1 reference

Progression, remission, regression of chronic renal diseases

31 March 2020

1 reference

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

31 March 2020

1 reference

Hypertension and nephropathy

31 March 2020

1 reference

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

31 March 2020

1 reference

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

31 March 2020

1 reference

Preventing microalbuminuria in type 2 diabetes

31 March 2020

1 reference

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

Combination ACEI and ARB therapy: additional benefit in renoprotection?

31 March 2020

1 reference

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

31 March 2020

1 reference

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

31 March 2020

Oral renin inhibitors

1 reference

Clinical Pharmacokinetics and Efficacy of Renin Inhibitors

31 March 2020

1 reference

Structure-based design of aliskiren, a novel orally effective renin inhibitor

31 March 2020

1 reference

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

31 March 2020

1 reference

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

31 March 2020

1 reference

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

31 March 2020

1 reference

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

31 March 2020

1 reference

Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade

31 March 2020

1 reference

The aggravating mechanisms of aldosterone on kidney fibrosis

31 March 2020

1 reference

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

31 March 2020

1 reference

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats

31 March 2020

1 reference

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

31 March 2020

1 reference

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

31 March 2020

1 reference

Regression of existing glomerulosclerosis by inhibition of aldosterone

31 March 2020

1 reference

Beneficial impact of spironolactone in diabetic nephropathy

31 March 2020

1 reference

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

31 March 2020

1 reference

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

31 March 2020

1 reference

Localization of endothelin peptides in human kidney

31 March 2020

1 reference

Endothelins in the normal and diseased kidney

31 March 2020

1 reference

Cloning and expression of a cDNA encoding an endothelin receptor

31 March 2020

1 reference

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

31 March 2020

1 reference

International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature

31 March 2020

1 reference

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

31 March 2020

1 reference

Venous smooth muscle contains vasoconstrictor ETB-like receptors

31 March 2020

1 reference

New therapeutics that antagonize endothelin: promises and frustrations

31 March 2020

1 reference

A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression

31 March 2020

1 reference

Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy

31 March 2020

1 reference

Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes

31 March 2020

1 reference

Effect of a specific endothelin A receptor antagonist on murine lupus nephritis

31 March 2020

1 reference

Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells

31 March 2020

1 reference

Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.

31 March 2020

1 reference

Bosentan therapy for pulmonary arterial hypertension

31 March 2020

1 reference

Noncholesterol-Lowering Effects of Statins

31 March 2020

1 reference

Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy

31 March 2020

1 reference

Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction

31 March 2020

1 reference

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?

31 March 2020

1 reference

Effect of combining ACE inhibitor and statin in severe experimental nephropathy

31 March 2020

1 reference

Meta-analysis: the effect of statins on albuminuria

31 March 2020

1 reference

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

31 March 2020

1 reference

Statins for improving renal outcomes: a meta-analysis

31 March 2020

1 reference

The safety of rosuvastatin: effects on renal and hepatic function

31 March 2020

1 reference

Study of Heart and Renal Protection (SHARP)

31 March 2020

1 reference

The TNF and TNF receptor superfamilies: integrating mammalian biology

31 March 2020

1 reference

Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis

31 March 2020

1 reference

TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction

31 March 2020

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations

31 March 2020

1 reference

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

31 March 2020

1 reference

Macrophages and progressive tubulointerstitial disease.

31 March 2020

1 reference

Blockade of CCR2 ameliorates progressive fibrosis in kidney.

31 March 2020

1 reference

RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis

31 March 2020

1 reference

A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation

31 March 2020

1 reference

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome

31 March 2020

1 reference

Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis

31 March 2020

1 reference

Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

31 March 2020

1 reference

Complement. First of two parts

31 March 2020

1 reference

The chemotactic receptor for human C5a anaphylatoxin

31 March 2020

1 reference

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

31 March 2020

1 reference

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

Experimental membranous nephropathy redux

31 March 2020

1 reference

TGF-beta isoforms in renal fibrogenesis

31 March 2020

1 reference

The logic of TGFbeta signaling.

31 March 2020

1 reference

Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity

31 March 2020

1 reference

Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

31 March 2020

1 reference

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

31 March 2020

1 reference

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis

31 March 2020

1 reference

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor

31 March 2020

1 reference

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

31 March 2020

1 reference

Pirfenidone improves renal function and fibrosis in the post-obstructed kidney

31 March 2020

1 reference

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis

31 March 2020

1 reference

Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.

31 March 2020

1 reference

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

31 March 2020

1 reference

Insulin resistance and its treatment by thiazolidinediones

31 March 2020

1 reference

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

31 March 2020

1 reference

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

31 March 2020

1 reference

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

31 March 2020

1 reference

Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

31 March 2020

1 reference

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

31 March 2020

1 reference

Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.

31 March 2020

1 reference

Rosiglitazone--continued uncertainty about safety

31 March 2020

1 reference

Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil.

31 March 2020

1 reference

Increased nephron oxygen consumption: potential role in progression of chronic renal disease

31 March 2020

1 reference

1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue

31 March 2020

1 reference

1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells

31 March 2020

1 reference

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

31 March 2020

1 reference

Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling

31 March 2020

1 reference

Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?

31 March 2020

1 reference

Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

31 March 2020

1 reference

Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats.

31 March 2020

1 reference

Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy

31 March 2020

1 reference

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

31 March 2020

1 reference

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

31 March 2020

1 reference

Connective tissue growth factor and renal diseases: some answers, more questions

31 March 2020

1 reference

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

31 March 2020

1 reference

Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis

31 March 2020

1 reference

Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis

31 March 2020

1 reference

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

31 March 2020

1 reference

Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease

31 March 2020

1 reference

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

31 March 2020

1 reference

A new look at platelet-derived growth factor in renal disease

31 March 2020

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

31 March 2020

1 reference

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

31 March 2020

1 reference

The mouse kinome: discovery and comparative genomics of all mouse protein kinases

31 March 2020

1 reference

CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases

31 March 2020

1 reference

Indirubin-3'-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling

31 March 2020

1 reference

The Notch pathway in podocytes plays a role in the development of glomerular disease

31 March 2020

1 reference

Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist

31 March 2020

1 reference

Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis

31 March 2020

1 reference

Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.

31 March 2020

1 reference

Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus

31 March 2020

1 reference

Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus

31 March 2020

1 reference

Therapeutics in renal disease: the road ahead for antiproliferative targets.

31 March 2020

1 reference

Notch signaling: cell fate control and signal integration in development

31 March 2020

1 reference

Therapeutic strategies for Alzheimer's disease

31 March 2020

1 reference

L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity

31 March 2020

1 reference

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

31 March 2020

1 reference

Inhibition of gamma-secretases alters both proliferation and differentiation of mesenchymal stem cells.

31 March 2020

1 reference

Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets

31 March 2020

1 reference

Latest treatment strategies for membranous nephropathy.

31 March 2020

1 reference

Rituximab for idiopathic membranous nephropathy

31 March 2020

1 reference

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

31 March 2020

1 reference

Hepatitis C virus: from entry to renal injury--facts and potentials.

31 March 2020

1 reference

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

31 March 2020

1 reference

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

31 March 2020

1 reference

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

31 March 2020

1 reference

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

31 March 2020

1 reference

ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease

31 March 2020

1 reference

Reversal of lesions of diabetic nephropathy after pancreas transplantation

31 March 2020

1 reference

New capillary growth: a contributor to regression of sclerosis?

31 March 2020

1 reference

The renal papilla is a niche for adult kidney stem cells

31 March 2020

1 reference

Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists

31 March 2020

1 reference

Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure

31 March 2020

1 reference

Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice

31 March 2020

1 reference

Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)

31 March 2020

1 reference

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

31 March 2020

1 reference

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

31 March 2020

1 reference

Fabry disease: guidelines for the evaluation and management of multi-organ system involvement

31 March 2020

1 reference

Autosomal dominant polycystic kidney disease

31 March 2020

1 reference

Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases

31 March 2020

1 reference

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

31 March 2020

1 reference

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

31 March 2020

1 reference

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

31 March 2020

1 reference

Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?

31 March 2020

1 reference

Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1.

31 March 2020

1 reference

Epithelial-mesenchymal transition and its implications for fibrosis

31 March 2020

1 reference

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

31 March 2020

1 reference

CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases

31 March 2020

1 reference

Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol

31 March 2020

1 reference

R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury

31 March 2020

1 reference

Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells

31 March 2020

1 reference

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2685

1 reference

Dimensions Publication ID

19 August 2017

1029514577

0 references

1 reference